Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction

Completed · Phase 2

Conditions studied: Impotence

In brief

To determine the onset of action, safety and toleration of different formulations and doses of UK-369,003 in patients with erectile dysfunction. Patients should have been previously treated with PDE5 inhibitors and have been responders to the drugs. Duration of treatment is 4 weeks.

Key facts

Study ID

NCT00141349

Run by

Pfizer

People needed

300

Starts

2005-02-01

Expected to finish

2005-08-01

Last updated by the study team

2006-07-25

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Erectile dysfunction as defined by DSM-IV. Patients should have been PDE5 inhibitor respondents

You may not qualify if…

• Alpha blockers and Nitrates of any preparation

Where it is running

• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Mesa, Arizona, United States
• Pfizer Investigational Site — Mesa, Arizona, United States
• Pfizer Investigational Site — Mesa, Arizona, United States
• Pfizer Investigational Site — Tempe, Arizona, United States
• Pfizer Investigational Site — Beverly Hills, California, United States
• Pfizer Investigational Site — San Bernardino, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Waterbury, Connecticut, United States
• Pfizer Investigational Site — Aventura, Florida, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — St. Petersburg, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Evansville, Indiana, United States
• Pfizer Investigational Site — Fort Wayne, Indiana, United States
• Pfizer Investigational Site — Jeffersonville, Indiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Milford, Massachusetts, United States
• Pfizer Investigational Site — Kansas City, Missouri, United States
• Pfizer Investigational Site — New Brunswick, New Jersey, United States
• Pfizer Investigational Site — Albany, New York, United States
• Pfizer Investigational Site — Endwell, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.